China SXT Pharmaceuticals, Inc.（SXTC）株——良い事業でしょうか？

China SXT Pharmaceuticals, Inc.（SXTC）株——良い事業でしょうか？ — InspectStocks

Keep exploring

The themes China SXT Pharmaceuticals is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

Highest-graded in Drug Manufacturers Specialty and Generic

Graded A or B and worth $2B or more: A first, then the largest.

All 78 graded companies in its industry

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

All grade rises

どうやって稼いでいるか

Regular traditional Chinese medicine pieces95%
Advanced traditional Chinese medicine pieces4%

売上構成比はyear ended March 31, 2026の推計であり、提出された報告書の数字ではありません。

競合

600518Kangmei Pharmaceutical Co., Ltd.
300147Xiangxue Pharmaceutical Co., Ltd.

何を売っているか6

Regular traditional Chinese medicine pieces
Medicinal plants processed into forms such as cut pieces or powders, generally prepared by boiling or decoction before use.
Directly-Oral advanced TCMP
Processed herbal medicines made to be taken by mouth without first being boiled as a decoction.
After-Soaking-Oral advanced TCMP
Small sealed bags of herbal material steeped in hot water to make an infusion.

さらに3件を表示

SanQiFen
A directly swallowed powder made from the roots and rhizomes of notoginseng.
CuYanHuSuo
A directly swallowed powder made from the tubers of Corydalis yanhusuo.
LuXueJing
A directly swallowed product made from dried deer blood.

誰が買っているか3

Hospitals, especially traditional Chinese medicine hospitals, buy products for patient care, mainly in Jiangsu province.
Pharmaceutical wholesalers buy products and distribute them to hospitals and other healthcare distributors.
As of March 31, 2026, end customers included 46 pharmaceutical companies, 11 chain pharmacies and 12 hospitals (March 31, 2026, high).

何に支えられ、何に崩されうるか

事業が頼っているもの

1Relies on medicinal-plant raw materials supplied by vendors in China.
2Relies on a limited number of customers; hospitals and pharmaceutical distributors account for important sales channels.
3Its business in China depends on contractual arrangements with Taizhou Suxuantang, a variable interest entity, rather than direct ownership of that operating company.

うまくいかなくなる可能性

1Losing or reducing sales to a small number of major customers could harm revenue.
2Disruptions in the supply of medicinal plants or other raw materials could interrupt production and deliveries.
3The company may be unable to enforce its contractual arrangements with Taizhou Suxuantang, or changes in Chinese rules may affect those arrangements or its ability to operate.

財務諸表をすべて見る →

China SXT Pharmaceuticals, Inc.について

China SXT makes traditional Chinese medicine pieces (TCMP) from medicinal plants, including herbs prepared as powders and other forms. In the fiscal year ended March 31, 2026, regular TCMP made up 95.02% of revenue (FY2026, high), while advanced TCMP made up 4.35% (FY2026, high); some advanced products can be swallowed directly or steeped in hot water. Total revenue was $1,138,052 (year ended March 31, 2026, high).

本社: Taizhou, Jiangsu, China
設立: 2017
従業員数: 56 full-time employees (March 31, 2026, high)
上場市場: Nasdaq Capital Market
決算期: March 31

China SXT Pharmaceuticals, Inc. 自身が米国証券取引委員会（SEC）に提出した書類にもとづきます。数字は報告されたままで、1 株当たりの履歴は今日の株数基準に修正済みです。これは事業の説明です——投資助言ではなく、売買を勧めるものでもありません。

Keep exploring

The themes China SXT Pharmaceuticals is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.